Jonathan Lei, PhD, Baylor College of Medicine, Houston, TX, comments on the clinical relevance of patient-derived xenografts (PDXs) in breast cancer research. PDX models demonstrate an 80% concordance with patient responses to taxane therapies, making them valuable tools for studying treatment efficacy. Despite their advantages, the absence of an immune system in PDX models limits their utility in evaluating immune-related therapies. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.